申联生物发布前三季度业绩，归母净利润28万元，同比扭亏为盈

Group 1 - The company reported a revenue of 238 million yuan for the first three quarters of 2025, representing a year-on-year decline of 4.27% [1] - The net profit attributable to the parent company was 280,000 yuan, marking a turnaround from a loss to profit year-on-year [1] - The non-recurring net profit showed a loss of 5.1 million yuan, indicating ongoing challenges in core operations [1] - The basic earnings per share were reported at 0 yuan [1]